Ambient air pollution, hot and cold temperature extremes and other factors associated with climate change are likely ...

Nektar Therapeutics NKTR announced that the phase IIb REZOLVE-AD study evaluating its lead pipeline candidate, ...

A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...

This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the ...

The Food and Drug Administration in February granted fast track designation for rezpegaldesleukin to treat adults and pediatric patients 12 years and up with moderate to severe atopic dermatitis, the ...

USA: Researchers have discovered in a new study that young children with moderate-to-severe atopic dermatitis (AD) tend to be ...

NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b ...

A new study published in the Journal of American Medical Association showed that dupilumab (Dupixent), used for treating ...

The use of dupilumab (Dupixent) for the treatment of atopic dermatitis was associated with an increased risk of psoriasis ...

Zai Lab Limited (NASDAQ:ZLAB) is one of the 10 biotech stocks screaming a buy. On June 17, the company delivered positive ...

Atopic dermatitis data from Nektar Therapeutics Inc. put investors even more in the mood for further results with rezpegaldesleukin (rezpeg), an IL-2 pathway agonist and regulatory T-cell proliferator ...

Finding an effective, safe medication to control itch is essential to maximize patient comfort. Because Zenrelia does not require a loading dose and is administered once daily, Zenrelia may help impro ...